ADIL
AdialยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ADIL Profile
Adial Pharmaceuticals, Inc.
A subsidiary of Adial that focused on developing novel molecules targeting the adenosine receptors
4870 Sadler Road, Suite 300, Glen Allen, Virginia 23060
--
Adial Pharmaceuticals, Inc., was incorporated as a Virginia limited liability company in November 2010. The company is a clinical-stage biopharmaceutical company focused on developing therapies to treat or prevent addiction and related diseases. The Company's investigational new drug candidate, AD04, is in development as a therapeutic agent for the treatment of alcohol use disorder (" AUD "). AD04 was recently studied in a Phase 3 clinical trial designated as the ONWARD trial for the potential treatment of AUD in subjects with certain target genotypes identified using a companion diagnostic genetic test.
